Boehringer Ingelheim: CVMP Adopts a Positive Opinion for SCOVELLA, First Therapy for Hyperinsulinaemia in Horses With Equine Metabolic Syndrome
November 10, 2026
November 10, 2026
INGELHEIM AM RHEIN, Germany, Nov. 10 (TNSrep)-- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
CVMP adopts a positive opinion for SCOVELLA(R), the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
Ingelheim, Germany 10/11/2026
* SCOVELLA(R) was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis - a common, painful inflamm . . .
* * *
CVMP adopts a positive opinion for SCOVELLA(R), the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
Ingelheim, Germany 10/11/2026
* SCOVELLA(R) was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis - a common, painful inflamm . . .
